Ignite Creation Date:
2024-05-06 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05690191
Status:
ENROLLING_BY_INVITATION
Last Update Posted:
2023-01-19
First Post:
2022-12-05
Brief Title:
Chidamide in Patients With Recurrent and Refractory Diffuse Large b
Sponsor:
Second Affiliated Hospital of Soochow University
Organization:
Second Affiliated Hospital of Soochow University
Study Overview
Official Title:
A Multicenter Prospective Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide cR2 in Real-world Practice in Patients With RelapsedRefractory Diffuse Large B-cell Lymphoma
Status:
ENROLLING_BY_INVITATION
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Multicenter Prospective Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide cR2 in Real-world Practice in Patients With RelapsedRefractory Diffuse Large B-cell Lymphoma
Detailed Description:
This is a prospective multicenter observational investigator-initiated clinical study The subjects were adults 18 years of age and older diagnosed with relapsedrefractory diffuse large B-cell lymphoma who will begin cR2 therapy at the time of enrollment Patients were required to complete a visit every 4 weeks lasting 24 weeks from the first dosing of the study protocol The first visit was considered an enrollment visit The specific dosage of cR2 will be determined according to the standard clinical practice of the treating physician Participation in the study did not affect treatment decisions Patients who could not continue with the cR2 regimen would terminate the visit early and then withdraw from the study According to the data collected from the experiment the safety and effectiveness of the research scheme were analyzed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None